GlassScriptPhysician profile
Caroline P Brown
NPI 1235660572
$2,203.94
in general payments reported to CMS, 2019-2025
24 companies · $879 in 2025
The $879 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $25.88 · 2022: $141 · 2023: $457 · 2024: $701 · 2025: $879.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,037.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,036.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $473.97 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $348.74 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Edwards Lifesciences Corporation | $156.51 | 2025 | |
| Pfizer INC. | $137.46 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $93.28 | 2022-2023 | |
| Lilly USA, LLC | $90.76 | 2023-2025 | Jardiance, Kisunla, Mounjaro |
| Glaxosmithkline, LLC. | $88.05 | 2024-2025 | Trelegy Ellipta |
| Amgen INC. | $87.87 | 2024-2025 | Otezla, Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $83.29 | 2023-2025 | |
| Dexcom, INC. | $74.46 | 2023-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.22 | 2024-2025 | Jardiance |
| Novo Nordisk INC | $69.91 | 2023-2025 | Wegovy, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.35 | 2024-2025 | Xifaxan |
| Exact Sciences Corporation | $62.28 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $58.79 | 2021-2024 | Freestyle Libre 3 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $46.18 | 2025 | Zoryve |
| Medtronic, INC. | $38.07 | 2023 | Intellis Adaptivestim, Vanta Adaptivestim |
| Corium, LLC | $32.62 | 2022 | |
| Astellas Pharma US INC | $30.98 | 2024 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $26.01 | 2022 | |
| Ironshore Pharmaceuticals INC. | $20.03 | 2024 | |
| Gilead Sciences, INC. | $15.94 | 2022 | |
| Tolmar, INC. | $15.45 | 2025 | Jatenzo |
| Supernus Pharmaceuticals, INC. | $13.72 | 2023 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.